Bile duct neoplasms are abnormal growths in the bile ducts. These growths can be benign (bile duct adenomas) or malignant (cholangiocarcinoma). Cholangiocarcinoma is the most prevalent type of cancer that develops from glandular cells that line the bile ducts and is divided into three locations, namely, intrahepatic, perihilar, and distal. Bile duct adenomas and other benign tumors are uncommon and frequently discovered by accident after surgery or autopsy. The bile duct neoplasms pipeline analysis by Expert Market Research focuses on various treatment options for this disease.
Major companies involved in the bile duct neoplasms pipeline analysis include Merck Sharp & Dohme LLC, Endeavor Biomedicines, Inc., and Carisma Therapeutics Inc., among others.
Leading drugs currently in the pipeline include pembrolizumab, and ENV- 101, among others.
Advancements in novel antiviral therapies and immune-modulating agents are driving pipeline growth. Increased investment in research and development, along with regulatory support, is accelerating clinical trials and new treatment approvals.
The Bile Duct Neoplasms Pipeline Analysis Report by Expert Market Research gives comprehensive insights into bile duct neoplasms currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Bile Duct Neoplasms therapeutics. The bile duct neoplasms report assessment includes the analysis of over 15 pipeline drugs and 10+ companies. The bile duct neoplasms pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with bile duct neoplasms treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to bile duct neoplasms.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Cholangiocytes give rise to bile duct neoplasms, which frequently entail chronic inflammation (from cholestasis, infections, or stones). It leads to genetic alterations which promote carcinogenesis, such as KRAS (early) and TP53 (late). Biliary intraepithelial neoplasia (BilIN) and intraductal papillary neoplasm (IPNB) are examples of premalignant lesions that show mucin production and papillary development. Long-term inflammation causes dysplasia, which damages the bile duct epithelium and creates a "vicious cycle" of cell division and DNA damage.
The resectable nature of bile duct neoplasm determines the course of treatment. The main treatment option is surgery, which may include resection of the liver or pancreas as well as excision of the bile duct. Chemotherapy (such as gemcitabine-cisplatin) and immunotherapy (such as pembrolizumab) aid in regulating tumor growth in situations that cannot be cured. Radiation therapy and photodynamic therapy relieve symptoms, whereas targeted therapies target mutations. Stent insertion is one palliative surgery that reduces jaundice and enhances quality of life.
Rare, bile duct neoplasm varies greatly in geography and demographics. About 8,000 cases of bile duct cancer are detected in the United States each year. Intrahepatic cancer is more common (1.49 per 100,000) than extrahepatic cancer (0.96 per 100,000). Infections with liver flukes are more common in Southeast Asia. Males and older persons are more likely to be impacted, and all groups continue to have low survival rates.
This section of the report covers the analysis of bile duct neoplasms drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total bile duct neoplasms clinical trials.
In the bile duct neoplasms pipeline, most candidates are in Phase II with 47% of the projects, followed by 35% in Phase I and 18% in Phase III demonstrating a broad spectrum of development stages and diverse progress toward potential treatments.
The drug molecule categories covered under the bile duct neoplasms pipeline analysis include monoclonal antibody, peptides, small molecule and gene therapy. The bile duct neoplasms report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Bile Duct Neoplasms.
The EMR report for the bile duct neoplasms pipeline analysis covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in bile duct neoplasms clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for bile duct neoplasms. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of bile duct neoplasms drug candidates.
Pembrolizumab, developed by Merck Sharp & Dohme LLC, is in Phase 3 of a clinical trial for treating biliary duct neoplasm. The trial evaluates its safety and efficacy, particularly in combination with chemotherapy, aiming to improve progression-free and overall survival. Pembrolizumab is an anti-PD-1 monoclonal antibody that boosts the immune system's ability to detect and fight cancer cells.
Endeavor Biomedicines’ ENV-101 is currently in Phase 2 of a clinical trial to treat bile duct neoplasms. In patients with solid tumors that have progressed, the trial assesses its safety, tolerability, and initial effectiveness. To reduce tumor growth and improve patient outcomes, ENV-101, an inhibitor of the hedgehog pathway, targets and blocks aberrant cell signaling.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Bile Duct Neoplasms Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for bile duct neoplasms. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into bile duct neoplasms collaborations, regulatory environments, and potential growth opportunities.
Hepatitis B Virus (HBV) Infection Drug Pipeline Analysis Report
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share